

FUSE MEDICAL, INC.

FORM 8-K (Current report filing)

Filed 12/03/21 for the Period Ending 11/29/21

Address 1565 NORTH CENTRAL EXPRESSWAY
SUITE 220
RICHARDSON, TX, 75080

Telephone 469-862-3030

CIK 0000319016

Symbol FZMD

SIC Code 5047 - Wholesale-Medical, Dental and Hospital Equipment and Supplies

Industry Medical Equipment, Supplies & Distribution

Sector Healthcare

Fiscal Year 12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 29, 2021

FUSE MEDICAL, INC.
(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation)	000-10093 (Commission File Number)	59-1224913 (IRS Employer Identification No.)
1565 North Central Expressway Suite 220 Richardson, Texas (Address of Principal Executive Offices)		75080 (Zip Code)

Registrant's Telephone Number, Including Area Code: (469) 862-3030

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	FZMD	OTCPink

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Section 1 - Registrant's Business and Operations

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 29, 2021, William E. McLaughlin, III resigned as Chief Financial Officer and as a Director of the Board of Fuse Medical, Inc. (the "Company") as well as from all other positions Mr. McLaughlin held with the Company and its subsidiaries. Mr. McLaughlin had no disagreements with the Company on any matter related to the Company's operations, policies or practices.

On December 3rd, 2021, Fuse Medical, Inc engaged CFO Consulting Partners, LLC to provide interim Chief Financial Officer (CFO) services, which include oversight and support to the current financial and operational processes and capabilities of the Company, while also providing organizational assessments and tool development while the Company searches for a permanent CFO.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Company Name
Date: November 29, 2021
By: /s/ Christopher C. Reeg
Christopher C. Reeg,
Chief Executive Officer and Director